<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019201</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065062</org_study_id>
    <secondary_id>NCI-96-C-0128</secondary_id>
    <nct_id>NCT00019201</nct_id>
    <nct_alias>NCT00001511</nct_alias>
  </id_info>
  <brief_title>Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer</brief_title>
  <official_title>PILOT STUDY OF THE CORRELATION BETWEEN THE FINDINGS OF ATYPICAL/MALIGNANT CELLS IN SPUTUM AND FLUORESCENCE BRONCHOSCOPY IN PATIENTS AT RISK FOR LUNG CANCER OF THE LIFE IMAGING SYSTEM AND WHITE LIGHT BRONCHOSCOPY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Fluorescent bronchoscopy, when used in combination with conventional white light&#xD;
      bronchoscopy, may improve the ability to detect early lung cancer.&#xD;
&#xD;
      PURPOSE: A pilot study to evaluate fluorescent light bronchoscopy plus conventional&#xD;
      bronchoscopy as a tool for screening and detecting lung cancer in persons with completely&#xD;
      resected head and neck cancer or successfully treated early-stage lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the efficacy of autofluorescence bronchoscopy using the Lung Imaging&#xD;
           Fluorescence Endoscopic System with conventional white-light bronchoscopy for the early&#xD;
           detection of lung cancer in selected patients with known or suspected bronchogenic&#xD;
           carcinoma, completely resected head and neck cancer, and successfully treated&#xD;
           early-stage lung cancer.&#xD;
&#xD;
        -  Determine the number of areas of moderate dysplasia, severe dysplasia, and carcinoma in&#xD;
           situ in patients treated with surgery for lung cancer compared with patients treated&#xD;
           with combined modality therapy.&#xD;
&#xD;
        -  Determine the ability of immunohistochemistry to predict whether lesions of moderate to&#xD;
           severe dysplasia will progress to cancer.&#xD;
&#xD;
      OUTLINE: If possible, patients produce a 3-day pooled sputum sample prior to bronchoscopy.&#xD;
      Patients then undergo tracheobronchial white-light bronchoscopy followed by autofluorescence&#xD;
      bronchoscopy using the Lung Imaging Fluorescence Endoscopic (LIFE) Device attached to a&#xD;
      computerized video camera. Visualized tissue is classified as either normal, abnormal, or&#xD;
      suspicious. Abnormal or suspicious tissue is biopsied, as is tissue from 1 or 2 randomly&#xD;
      chosen normal sites. Immunohistochemical analysis of the biopsy material is conducted without&#xD;
      knowledge of the bronchoscopic results. Patients unable to produce a sputum sample prior to&#xD;
      bronchoscopy are required to do so after bronchoscopy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 70 patients will be entered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1996</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Screening</primary_purpose>
  </study_design_info>
  <condition>Head and Neck Cancer</condition>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cytology specimen collection procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sputum cytology</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bronchoscopic and lung imaging studies</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bronchoscopy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>comparison of screening methods</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  The following diagnoses are eligible:&#xD;
&#xD;
               -  Known or suspected bronchogenic carcinoma scheduled for bronchoscopy as part of&#xD;
                  standard diagnostic or staging work-up&#xD;
&#xD;
               -  Completely resected stage I/II non-small cell lung cancer with no evidence of&#xD;
                  metastasis&#xD;
&#xD;
               -  Stage III non-small cell lung cancer with no evidence of disease for at least 2&#xD;
                  years following treatment&#xD;
&#xD;
               -  Small cell lung cancer with no evidence of disease for at least 2 years following&#xD;
                  treatment&#xD;
&#xD;
               -  Completely resected head and neck cancer with no evidence of metastasis&#xD;
&#xD;
          -  Ability to produce sputum samples required&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC 2,000-20,000&#xD;
&#xD;
          -  Platelets at least 50,000&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled hypertension (i.e., systolic pressure greater than 200 mm Hg or&#xD;
             diastolic pressure greater than 120 mm Hg)&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No bleeding disorder&#xD;
&#xD;
          -  No allergic reaction to topical lidocaine&#xD;
&#xD;
          -  No pregnant women&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 18 months since ionizing radiotherapy to the chest&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 1 month since yttrium-aluminum-garnet (YAG) laser therapy to the lung&#xD;
&#xD;
          -  At least 3 months since fluorescent photosensitizing drugs (e.g., Photofrin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Michael Hamilton, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2000</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage III non-small cell lung cancer</keyword>
  <keyword>limited stage small cell lung cancer</keyword>
  <keyword>stage I nasopharyngeal cancer</keyword>
  <keyword>stage II nasopharyngeal cancer</keyword>
  <keyword>stage III nasopharyngeal cancer</keyword>
  <keyword>stage I lip and oral cavity cancer</keyword>
  <keyword>stage II lip and oral cavity cancer</keyword>
  <keyword>stage III lip and oral cavity cancer</keyword>
  <keyword>stage I hypopharyngeal cancer</keyword>
  <keyword>stage II hypopharyngeal cancer</keyword>
  <keyword>stage III hypopharyngeal cancer</keyword>
  <keyword>stage I laryngeal cancer</keyword>
  <keyword>stage II laryngeal cancer</keyword>
  <keyword>stage III laryngeal cancer</keyword>
  <keyword>stage I paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage II paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage III paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage I oropharyngeal cancer</keyword>
  <keyword>stage II oropharyngeal cancer</keyword>
  <keyword>stage III oropharyngeal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

